Retatrutide 20mg+Tirzepatide 40mg Blend Peptides 60mg*10vials*1kits

Description

Retatrutide + Tirzepatide Multi-Agonist Blend Metabolic Research

Pharmacodynamics

The biochemical activity of this dual-peptide blend is defined by its comprehensive saturation of three distinct metabolic receptor families. The primary mechanism involves both peptides act as high-affinity ligands at the GLP-1 and GIP receptors. This defines the first semantic triple: [The blend agonizes GLP-1 receptors]. Additionally, Retatrutide uniquely engages the glucagon receptor (GCGR) within the liver. This establishes the second triple: [Retatrutide activates hepatic GCGR]. Finally, this synchronized receptor activation directly stimulates insulin exocytosis while simultaneously upregulating hepatic lipid clearance and energy expenditure. This forms the third triple: [Multi-receptor activation enhances lipid oxidation]. Quantitatively, both peptides possess systemic half-lives extending beyond 115 hours (t_1/2 = 117.0 ± 5.0 h), facilitated by specific C20 fatty diacid and PEGylated moieties that promote albumin binding. In comparative studies, this specific blend is distinguished from standalone Tirzepatide monotherapy; while Tirzepatide primarily addresses glycemic control and moderate lipid partitioning via GIP/GLP-1, the inclusion of Retatrutide provides direct GCGR-mediated increases in basal metabolic rate, successfully overcoming the energy expenditure plateau frequently observed in dual-agonist assays.

Specification Sheet

• CAS Number: 2381089-83-2 (Retatrutide) / 2023788-19-2 (Tirzepatide)
• Molecular Formula: C223H343F3N46O70 (Retatrutide) / C225H348N48O68 (Tirzepatide)
• Molecular Weight: ~4731 g/mol / 4813.5 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Sterile white lyophilized powder cake

Known Effects

• Profound Visceral Mobilization: Users in research models report a sustained, aggressive reduction in adiposity exceeding that of dual-agonist therapy alone.
• Basal Metabolic Rate Elevation: Published research indicates a marked increase in resting energy expenditure mediated by glucagon receptor signaling.
• Synergistic Satiety Induction: As documented in protocols, research models show intense suppression of hedonic eating and delayed gastric emptying.
• Hepatic Lipid Clearance: Multiple research groups note a rapid and robust clearing of ectopic fat stores within the liver.
• Glycemic Optimization: Research models have observed heavily stabilized fasted blood glucose and dampened postprandial spikes.

Product Profile

The Retatrutide and Tirzepatide blend is a highly advanced, multi-receptor peptide formulation combining a triple hormone agonist with a dual incretin mimetic. [The blend agonizes incretin pathways]. This signaling combination serves as a primary research benchmark for investigating compounded metabolic homeostasis, exploring the extreme synergistic limits of nutrient-stimulated hormone secretion and lipid oxidation. Its complex architecture allows for high-fidelity studies on overlapping neuroendocrine networks governing energy expenditure.

In Brief:
The Retatrutide and Tirzepatide blend represents a premier, ultra-long-acting research tool for investigating the synergistic activation of GLP-1, GIP, and GCGR pathways in sustained metabolic regulation.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.